Results 321 to 330 of about 1,467,646 (404)

Next‐Generation HER‐2 Tumor‐Targeted Delivery of the STING Agonist Immune‐Stimulating Antibody Conjugate (ISAC) Improves Anticancer Efficacy and Induces Immunological Memory

MedComm, Volume 6, Issue 7, July 2025.
A novel immune‐stimulating antibody‐drug conjugate, which links STING agonists to anti‐HER2 mAb through an optimized noncleavable Linker, remains highly stable at DAR = 5.7 and demonstrates superior efficacy over marketed HER2‐targeted ADCs in multiple tumor models with high, low, and drug‐resistant HER2 expression.
Gang Wu, Chuanfei Yu, Chunyong Ding, Shengtao Yao, Jialiang Du, Zhihao Fu, Yu Liu, Yiming Fan, Guanghao Wu, Ao Zhang, Junzhi Wang   +10 more
wiley   +1 more source

A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies. [PDF]

Mol Cancer Ther
Moore GL, Zeng VG, Diaz JE, Bonzon C, Avery KN, Rashid R, Qi J, Nam DH, Jacinto J, Dragovich MA, Kim YK, Balcazar KP, Bakhit CG, Eivazi A, Nguyen H, Muchhal US, Szymkowski DE, Desjarlais JR, Hedvat M.   +18 more
europepmc   +1 more source

Autoimmune Diseases: Molecular Pathogenesis and Therapeutic Targets

MedComm, Volume 6, Issue 7, July 2025.
This review provides a comprehensive overview of common autoimmune diseases, details clinical manifestations and summarizes the pathogenesis, including the breakdown of immune tolerance, initiation of autoimmune responses, and their progressive amplification.
Xiaoshuang Song, Hantian Liang, Fang Nan, Wenjing Chen, Junyao Li, Liu He, Yiping Cun, Zhenhong Li, Wei Zhang, Dunfang Zhang   +9 more
wiley   +1 more source

Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma. [PDF]

J Immunother Cancer
Kolbe C, Kauer J, Brinkmann B, Dreger P, Huber W, Müller-Tidow C, Dietrich S, Roider T.   +7 more
europepmc   +1 more source

Sjögren's Syndrome: Epidemiology, Classification Criteria, Molecular Pathogenesis, Diagnosis, and Treatment

MedComm, Volume 6, Issue 7, July 2025.
A brief view of possible etiologic events preceding the diagnosis of desiccation syndrome. ABSTRACT Sjögren's syndrome (SS) is a chronic autoimmune disorder characterized by T‐cell‐mediated B‐cell hyperactivity and cytokine production, clinically manifesting, dry mouth and eyes, accompanied by pain and fatigue.
Ying Hu, Bin Wen, Yunfei Zhang, Xiaocui Wang, Xuemei Duan, Haonan Li, Yufeng Fan, Huifeng Shang, Yukai Jing   +8 more
wiley   +1 more source

Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma. [PDF]

Mol Cancer Ther
Habibollahi P, Gurevich A, Hui JZ, Weinfurtner K, McClung G, Adler J, Soulen MC, Kaplan DE, Nadolski GJ, Hunt SJ, Tsourkas A, Gade TP.   +11 more
europepmc   +1 more source

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group

British Journal of Haematology, Volume 207, Issue 1, Page 110-122, July 2025.
Summary Developing new therapeutic regimens for relapsed/refractory (R/R) B non‐Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti‐CD20‐containing ...
Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah, Stéphanie Guidez, Olivier Casasnovas, Pierre Feugier, Gandhi Damaj, Hervé Tilly, Loïc Ysebaert, Steven Le Gouill, Nadine Morineau, Emmanuel Gyan, Rémy Gressin, Roch Houot, Morgane Cheminant, Franck Morschhauser, Catherine Thieblemont, Corinne Haioun, Emmanuelle Nicolas‐Virelizier, Luc‐Matthieu Fornecker, Nicolas Daguindau, Guillaume Cartron   +21 more
wiley   +1 more source

A two-column process for bispecific antibody purification based on MabSelect VL resin's strong byproduct removal capability. [PDF]

J Biol Methods
Dong W, Zhang P, Wu D, Wan Y, Li Y.
europepmc   +1 more source

The role of blinatumomab in adult acute B lymphoblastic leukaemia

British Journal of Haematology, Volume 207, Issue 1, Page 27-42, July 2025.
Blinatumomab, a CD19‐directed bispecific T‐cell engager, has become a crucial part of BCP‐ALL therapy in r/r disease, MRD‐positive disease and has recently been implemented into first‐line therapy of BCP‐ALL. This review discusses important clinical trials with a focus on blinatumomab in first‐line therapy of adult BCP‐ALL.
Anne C. Wilke, Nicola Gökbuget
wiley   +1 more source

TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8⁺ T cell function. [PDF]

Oncoimmunology
Wang R, Xu J, Cheng S, Ling Z, Sonam W, Yang J, Jin F, Wen J, Lu X, Ma L, Zhang Y, Sun X, Yi C, Sun B.   +13 more
europepmc   +1 more source